Ocugen, Inc. (OCGN)
NASDAQ: OCGN · Real-Time Price · USD
0.7995
+0.0756 (10.44%)
At close: Mar 28, 2025, 4:00 PM
0.7710
-0.0285 (-3.56%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Ocugen Employees
Ocugen had 95 employees as of December 31, 2024. The number of employees increased by 30 or 46.15% compared to the previous year.
Employees
95
Change (1Y)
30
Growth (1Y)
46.15%
Revenue / Employee
$42,684
Profits / Employee
-$568,989
Market Cap
233.47M
Employees Chart
OCGN News
- 10 days ago - Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - GlobeNewsWire
- 23 days ago - Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 4 weeks ago - Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease - GlobeNewsWire
- 5 weeks ago - Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 6 weeks ago - Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewsWire
- 7 weeks ago - Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa - GlobeNewsWire
- 2 months ago - Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 - GlobeNewsWire